How to respond to signs of mild cognitive impairment and memory loss
Q. Two members of our book group have early signs of cognitive impairment. We have become so close after 10 years of being ...
Repetitive transcranial magnetic stimulation enhances tai chi chuan–linked benefits, study claims
Fujian University of Traditional Chinese Medicine in China has reported that repetitive transcranial magnetic stimulation ...
Independent.ie on MSN22h
Ask the doctor: My elderly mother is getting forgetful and searching for words. Is this the start of dementia?
Question: My mother in her 70s has mild cognitive impairment. She searched for words and forgets thing. It doesn’t majorly impact day to day life, but is this a definite pre-cursor for dementia? I am ...
New criteria developed for appropriate use of cognitive impairment imaging tools
Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the ...
News Medical on MSN4d
Air pollution amplifies dementia risk in cardiometabolic disease patients - healthy habits can help
CMD patients face a 2x higher risk of dementia and MCI, but healthier lifestyles can counter air pollution's impact and ...
Dementia Risk May Be Doubling, New Study Says—Here’s What You Can Do About It
We all forget things now and then—people’s names, where you put your car keys, that dentist appointment that was scheduled ...
HealthDay on MSN6d
Dementia Index Shows Validity for Predicting Age of Onset of MCI, Alzheimer Disease
The Florey Dementia Index (FDI) is valid for predicting the age of onset of mild cognitive impairment (MCI) and Alzheimer ...
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...
Hosted on MSN2d
New Criteria Developed for Appropriate Use of Amyloid, Tau PET
Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the ...
FDA Accepts Eisai And Biogen's BLA For Subcutaneous LEQEMBI For Early Alzheimer's Disease
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...
FDA Accepts LEQEMBI (Lecanemab-Irmb) Biologics License Application For Subcutaneous Maintenance Dosing For The Treatment Of Early Alzheimer's Disease
( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...